A B S T R A C T Tissue somatostatin-like immunoreactivity (SLI) consists of a number of molecular species including the cyclic tetradecapeptide or SRIF, an Nterminally extended form of SRIF termed somatostatin-28, as well as larger precursor peptides. The function and nature of circulating SLI is not well understood. In this report, we describe techniques for the definition of the components of plasma SLI in normal human plasma. Plasma SLI measured after gel filtration on Bio-gel P-6 columns was found to consist of from 1-3 peaks. The void volume peak was present in greatest concentration (34.2±8.9 pg/ml) and did not increase in response to a mixed meal. Very low levels of two additional peaks of SLI activity were found. To further characterize these peaks, 10-ml plasma samples were extracted and concentrated on octadecylsilyl silica (C-18) cartridges with subsequent fractionation on Bio-gel P-6 columns. The two peaks that coeluted with synthetic SRIF and S-28 markers, respectively, were present in concentrations of 5.4±1.4 and 4.8±1.9 pg/ml in fasting plasma. In response to a mixed meal, the SLI14 peak doubled (12.9±2.4 pg/ml) while the SLI28 peak increased to 29.9±7.2 pg/ml at 120 min. These results provide evidence that S-28 circulates in human plasma and its increase after feeding is consistent with a possible biological role for this peptide.
INTRODUCTION
Recent studies have focused on the distribution of and relationship between the various molecular forms of somatostatin (1) (2) (3) (4) (5) . Thus the cyclic tetradecapeptide somatostatin (SRIF)' initially identified in the hypothalamus is also present in other areas of the brain, the pancreas and gastrointestinal tract (3) . The 28 amino acid form of somatostatin (S-28), which consists of SRIF with an NH2 terminal extension, is the predominant form of somatostatin in the intestinal mucosa but is also found in the hypothalamus and pancreas (2) . It has also been demonstrated that cultured hypothalamic neurons are capable of synthesizing a 15,000-mol wt form of somatostatin-like immunoreactivity (SLI) in addition to SRIF and S-28 (5). The 15,000 mol wt SLI is involved in two potential biosynthetic pathways leading to SRIF; either directly or via S-28 as an intermediate.
Circulating forms of both S-28 and SRIF have been identified in the portal vein of rats by Patel et al. (2) and we have made similar observations in the portal and peripheral circulation of rats and dogs (6) . S-28 has not been previously identified in human plasma and its physiological function remains uncertain. This study was therefore undertaken to determine if S-28 could be detected in human plasma and to define the responses of plasma SLI component fractions following ingestion of a mixed meal.
METHODS
Subjects. Experiments were performed in five healthy human volunteers (age 28.6±2.5 yr) who were all within 110% of ideal body wt. Written informed consent was obtained and the study was approved by the Clinical Investigation Committee of the University of Chicago. After an overnight fast peripheral venous samples for the measurement of plasma SLI were drawn into chilled tubes containing Trasylol (500 KIU/ml) and EDTA (1.2 mg/ml). Each subject then consumed a mixed meal consisting of 710 cal made of 94.6 g carbohydrate, 26 g protein, and 25.2 g fat (Ensure plus, Ross Laboratories, Columbus, OH). Postmeal samples were obtained at 30-min intervals for a total of 180 min. Plasma was separated immediately and stored at -20'C until assayed.
Assays. Plasma glucose was measured using a glucose analyzer (Yellow Springs Instrument Co., Yellow Springs, OH). SLI was measured by radioimmunoassay in 0.1 M sodium citrate buffer containing 0.1% BSA and 0.2% sodium azide, pH 5.0 as previously described (6 1 pg/tube for SRIF and 4 pg/tube for S-28. Interassay variation was ±9.4% and intraassay variation was ±6.7%. Gel chromatography. Gel chromatography of plasma was performed on Bio-gel P-6 columns (1 X 47 cm) equilibrated in the assay buffer. 1-ml plasma samples from the fasting and 120-min sampling times were applied to the columns. SLI was eluted under gravity at a flow rate of 0.1 ml/min. Aliquots (0.5 ml) were collected and the entire fraction assayed for its SLI content. Recovery of SRIF and S-28 standards added to the column was >90%. Recovery of total plasma SLI added to the columns was 96.2±9.1% (n = 10).
Concentration of plasma. In view of the low levels of SLI components found in 1 ml of plasma, additional aliquots of plasma drawn at the fasting and 120 min sampling times were concentrated in the following manner: 10 ml plasma was diluted twofold with 1% trifluoroacetic acid (TFA). The mixture was passed through a reverse-phase octadecylsilyl silica (C-18) cartridge (Sep-pak, Waters Co., Inc., Milford, MA) to which the SLI adsorbed. The cartridge was rinsed with 5 ml 1% TFA and the SLI was eluted with 1.5 ml of a mixture of acetonitrile, water, and TFA (400:99:1). The extract was dried by rotary evaporation and reconstituted in 1 ml assay buffer. SLI was then measured directly or after gel filtration chromatography.
Additional validation of the techniques for concentration and chromatographic separation of the plasma SLI components was performed as follows. E. Chromatography of 1-ml plasma samples on Bio-gel P-6 columns showed that the SLI eluted from the columns in three discrete peaks (Table I, and Fig. 2) . A void volume SLI peak was measured in each subject; its concentration did not increase significantly after feeding. In the fasting state low levels of an intermediate sized peak that coeluted with synthetic S-28 (SLI28) was present in one of the five subjects. However 120 min postprandially this peak was detectable in all subjects and increased in the subject in whom it had previously been detected. A low molecular weight peak that coeluted with synthetic SRIF (SLI'4) was detected in one of the five subjects in the fasting sample and low concentrations of this peak appeared after the meal in each subject.
When 10-ml plasma samples were extracted on C-18 cartridges and then chromatographed on Bio-gel P-6 columns the void volume peak was almost totally eliminated (Table I and Fig. 2 ). Two peaks, coeluting with S-28 (SLI28) and SRIF (SLI'4) were present in both the fasting and postprandial samples. The concentration of SL128 increased from a basal level of 48.4±19.1 pg/10 ml to 299.4±71.8 pg/10 ml (P < 0.01) at 120 min after the meal stimulus. The SLI'4 peak increased from a fasting concentration of 53.6±14.4 pg/10 ml to 129±24.0 pg/10 ml (P < 0.005) 120 min postprandially.
DISCUSSION
The measurement of SLI in human plasma is difficult for a variety of reasons: (a) plasma SLI consists of heterogeneous components of different molecular size, Results are expressed as total SLI (picograms)/peak. The SLI levels in the SLIVO and SLI'4 peaks were read off an SRIF standard curve and the SLIM levels were read off an S-28 standard curve. The values in panel A represent SLI content of each peak obtained after gel filtration of 1 ml of plasma on Bio-gel P-6 columns. Recovery of total plasma SLI added to the columns was 96.2±9.1% (n = 10).The values in panel B represent the SLI content of each peak obtained after extraction of 10 ml of plasma on C-18 cartridges with subsequent gel filtration of the extract on Bio-gel P-6 columns. The value for the SLI content in each peak in panel B was divided by 10 to facilitate comparison with the values in panel A. each of which is present in very low concentration (7-9); (b) circulating somatostatin binding factors that interfere with the somatostatin assay, have been reported (8, 9) and (c) proteolytic enzymes in plasma have been shown to degrade the SRIF tracer under certain conditions (7, 9, 10) . These methodological difficulties have resulted in significant controversy concerning the level and nature of circulating SLI. Thus while some investigators have described circulating SLI levels to be <100 pg/ml in man (9-11), others have reported concentrations that are considerably higher (7, 12) . Although most studies have indicated that the void volume peak of immunoreactivity is the predominant circulating SLI component (8, 9), Kronheim et al. (7) suggested that the lower molecular weight form is present in greatest concentration.
In the present studies we have utilized a variety of approaches to overcome the methodological problems associated with the radioimmunoassay of plasma SLI. Fortunately, the unusual binding characteristics of our antibody, R3b, permitted a sensitive radioimmunoassay to be performed at pH 5.0, under which conditions degradation of 251I-Tyr'-SRIF tracer is completely inhibited (12) . The full characterization of plasma SLI requires its separation into its component peaks on gel columns. Thus gel filtration chromatography of 1-ml plasma samples showed the predominant circulating form of plasma SLI in both the fasting state and postprandially to be the void volume component, whose concentration (34.2±8.9 pg/ml) did not increase in response to feeding. The components of SLI that coelute with SRIF and S-28 were not consistently found in the fasting state by this technique, presumably due to their low levels and to the significant dilution factor inherent in the column separation procedure. Furthermore, the low levels of SLI28 (12±1.0 pg/ml) and SLI14 (3.2±0.8 pg/ml) present after feeding made accurate quantitation of these peaks difficult when whole plasma was separated on columns. We therefore concentrated 10 ml plasma on C-18 cartridges. This allowed the measurement of very low concentrations of plasma SLI and facilitated accurate chromatographic separation of its various components. In addition it eliminated the void volume immunoreactivity, which is probably due to a cross-reacting protein unrelated to physiologically active somatostatin. The results of these experiments indicate that fasting plasma clearly contains both SLI28 (48.4±19.1 pg/10 ml) and SLI14 (53.6±14.4 pg/10 ml). Furthermore, 120 min after feeding, the levels of SLI28 increased sixfold over base line to 299.4±71.8 pg/10 ml and levels of SLI14 doubled to 129±24.0 pg/10 ml.
It is evident from Fig. 2 and Table I that the total SLI level recovered in the SLI"4 and SLI28 peaks after extraction of 10 ml of plasma represents a >10-fold increase over the level in each of these peaks measured after gel filtration of 1 ml of unextracted plasma. However, when known concentrations of SRIF and S-28 were added to plasma and then subjected to the same Plasma Somatostatin 28 Increases in Response to Feeding in Man 20 -extraction procedure the recovery of these peptides was 92.8±7.1 and 83±4%, respectively. Furthermore, extraction of increasing volumes of aliquots of the same plasma resulted in a linear increase in the measured SLI levels (coefficient of variation, +6.7%). Therefore, the apparent over-recovery of the SLI'4 and SLI28 peaks obtained from 10-ml samples in comparison to 1-ml samples is probably related to dilution of SLI in the 1-ml samples below the sensitivity of the assay. Thus, in Fig. 2 , panel C, the peaks of SLI14 and SLI28 are narrow comprising only three to four column fractions after chromatography of 1 ml of plasma. In contrast, as shown in panel D, the SLI in each of these peaks is above the detection limit of the assay in 8-10 column fractions after concentration and extraction of a 10-ml plasma sample.
The physiological significance of plasma SLI and its constituent components is at present uncertain. Zyznar et al. (11) reported that the total plasma SLI concentration increased from 8 to 20 pg/ml after feeding. Furthermore, they found that infusion of SRIF at a rate calculated to mimic this increase in plasma SLI had physiological effects resulting in suppression of plasma insulin and glucagon levels. In this study we have documented that in response to feeding there is an increase not only in the level of SLI14 but also a consistently greater increase in levels of circulating SLI28. In view of the fact that S-28 is more active than SRIF in some biological systems (13) , and since its plasma clearance rate is slower than that of SRIF (14) , circulating SLI28 may constitute the major biologically active plasma SLI component. It has recently been suggested that S-28 is not merely a biosynthetic precursor of SRIF (5) but a physiologically distinct peptide. Thus S-28 has greater affinity for pituitary receptors than SRIF but a lower affinity for brain receptors (15) . Furthermore, its tissue distribution in the central nervous system as well as the gastrointestinal tract and pancreas is discrete from that of SRIF (2) . In the light of these differences between the two peptides it is important that future studies that aim to define the role of plasma SLI in normal physiological responses, as well as disease states, give due consideration to the relative contributions of the void volume, SLI"4 and SLI28 peaks to total plasma SLI.
